APO Research
Talk to an analyst

APO RESEARCH · REPORT

Living Biological Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Living Biological Drugs Market Analysis and Forecast 2026-2032

17 January 2026216 pages

Choose your research edition.

Industry ResearchLiving Biological Drugs Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Living Biological Drugs Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Living Biological Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Living Biological Drugs Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Living Biological Drugs Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Living Biological Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Living Biological Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Living Biological Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Living Biological Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Living Biological Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Living Biological Drugs include Ardeypharman, Miyarisan Pharmaceutical, Ferring Pharmaceuticals, Seres Therapeutics, Infant Bacterial Therapeutics, Osel, Takeda, AOBiome and Synlogic, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Living Biological Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Living Biological Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Living Biological Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Living Biological Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Living Biological Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Living Biological Drugs revenue, projected growth trends, production technology, application and end-user industry.

Living Biological Drugs Segment by Company

Ardeypharman

Miyarisan Pharmaceutical

Ferring Pharmaceuticals

Seres Therapeutics

Infant Bacterial Therapeutics

Osel

Takeda

AOBiome

Synlogic

Finch Therapeutics

Capsugel

Jeneil Biotech

UAS Labs

Biose

Cerbios-Pharma

Inpac Probiotics

NIZO

Winclove Probiotics

BJP Laboratories

Luina Bio

List Labs

MatriSys Bioscience

Living Biological Drugs Segment by Type

Single Strain

Multi Strain

Co-Culture

Living Biological Drugs Segment by Application

Digestive System

Urinary System

Skin System

Living Biological Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Living Biological Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Living Biological Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Living Biological Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Living Biological Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Living Biological Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Living Biological Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Living Biological Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Single Strain Major Player Table 3. Multi Strain Major Player Table 4. Co-Culture Major Player Table 5. Global Living Biological Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Digestive System Major Player Table 7. Urinary System Major Player Table 8. Skin System Major Player Table 9. Living Biological Drugs Industry Trends Table 10. Living Biological Drugs Industry Drivers Table 11. Living Biological Drugs Industry Opportunities and Challenges Table 12. Living Biological Drugs Industry Restraints Table 13. Global Living Biological Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Living Biological Drugs Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Living Biological Drugs Market Share by Region (2021-2026) Table 16. Global Living Biological Drugs Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Living Biological Drugs Market Share by Region (2027-2032) Table 18. Global Living Biological Drugs Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Living Biological Drugs Revenue Market Share by Players (2021-2026) Table 20. Global Living Biological Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Living Biological Drugs Key Players Headquarters & Area Served Table 22. Global Living Biological Drugs Players, Product Type & Application Table 23. Global Living Biological Drugs Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Living Biological Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Living Biological Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Living Biological Drugs Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Living Biological Drugs Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Living Biological Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Living Biological Drugs Revenue Market Share by Type (2027-2032) Table 31. Global Living Biological Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Living Biological Drugs Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Living Biological Drugs Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Living Biological Drugs Revenue Market Share by Application (2021-2026) Table 35. Global Living Biological Drugs Revenue Market Share by Application (2027-2032) Table 36. Ardeypharman Company Information Table 37. Ardeypharman Business Overview Table 38. Ardeypharman Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Ardeypharman Living Biological Drugs Product Portfolio Table 40. Ardeypharman Recent Development Table 41. Miyarisan Pharmaceutical Company Information Table 42. Miyarisan Pharmaceutical Business Overview Table 43. Miyarisan Pharmaceutical Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Miyarisan Pharmaceutical Living Biological Drugs Product Portfolio Table 45. Miyarisan Pharmaceutical Recent Development Table 46. Ferring Pharmaceuticals Company Information Table 47. Ferring Pharmaceuticals Business Overview Table 48. Ferring Pharmaceuticals Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Ferring Pharmaceuticals Living Biological Drugs Product Portfolio Table 50. Ferring Pharmaceuticals Recent Development Table 51. Seres Therapeutics Company Information Table 52. Seres Therapeutics Business Overview Table 53. Seres Therapeutics Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Seres Therapeutics Living Biological Drugs Product Portfolio Table 55. Seres Therapeutics Recent Development Table 56. Infant Bacterial Therapeutics Company Information Table 57. Infant Bacterial Therapeutics Business Overview Table 58. Infant Bacterial Therapeutics Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Infant Bacterial Therapeutics Living Biological Drugs Product Portfolio Table 60. Infant Bacterial Therapeutics Recent Development Table 61. Osel Company Information Table 62. Osel Business Overview Table 63. Osel Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Osel Living Biological Drugs Product Portfolio Table 65. Osel Recent Development Table 66. Takeda Company Information Table 67. Takeda Business Overview Table 68. Takeda Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Takeda Living Biological Drugs Product Portfolio Table 70. Takeda Recent Development Table 71. AOBiome Company Information Table 72. AOBiome Business Overview Table 73. AOBiome Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. AOBiome Living Biological Drugs Product Portfolio Table 75. AOBiome Recent Development Table 76. Synlogic Company Information Table 77. Synlogic Business Overview Table 78. Synlogic Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Synlogic Living Biological Drugs Product Portfolio Table 80. Synlogic Recent Development Table 81. Finch Therapeutics Company Information Table 82. Finch Therapeutics Business Overview Table 83. Finch Therapeutics Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Finch Therapeutics Living Biological Drugs Product Portfolio Table 85. Finch Therapeutics Recent Development Table 86. Capsugel Company Information Table 87. Capsugel Business Overview Table 88. Capsugel Living Biological Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Capsugel Living Biological Drugs Product Portfolio Table 90. Capsugel Recent Development Table 91. Jeneil Biotech Company Information Table 92. Jeneil Biotech Business Overview Table 93. Jeneil Biotech Living Biological Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Jeneil Biotech Living Biological Drugs Product Portfolio Table 95. Jeneil Biotech Recent Development Table 96. UAS Labs Company Information Table 97. UAS Labs Business Overview Table 98. UAS Labs Living Biological Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. UAS Labs Living Biological Drugs Product Portfolio Table 100. UAS Labs Recent Development Table 101. Biose Company Information Table 102. Biose Business Overview Table 103. Biose Living Biological Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Biose Living Biological Drugs Product Portfolio Table 105. Biose Recent Development Table 106. Cerbios-Pharma Company Information Table 107. Cerbios-Pharma Business Overview Table 108. Cerbios-Pharma Living Biological Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Cerbios-Pharma Living Biological Drugs Product Portfolio Table 110. Cerbios-Pharma Recent Development Table 111. Inpac Probiotics Company Information Table 112. Inpac Probiotics Business Overview Table 113. Inpac Probiotics Living Biological Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Inpac Probiotics Living Biological Drugs Product Portfolio Table 115. Inpac Probiotics Recent Development Table 116. NIZO Company Information Table 117. NIZO Business Overview Table 118. NIZO Living Biological Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. NIZO Living Biological Drugs Product Portfolio Table 120. NIZO Recent Development Table 121. Winclove Probiotics Company Information Table 122. Winclove Probiotics Business Overview Table 123. Winclove Probiotics Living Biological Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Winclove Probiotics Living Biological Drugs Product Portfolio Table 125. Winclove Probiotics Recent Development Table 126. BJP Laboratories Company Information Table 127. BJP Laboratories Business Overview Table 128. BJP Laboratories Living Biological Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. BJP Laboratories Living Biological Drugs Product Portfolio Table 130. BJP Laboratories Recent Development Table 131. Luina Bio Company Information Table 132. Luina Bio Business Overview Table 133. Luina Bio Living Biological Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Luina Bio Living Biological Drugs Product Portfolio Table 135. Luina Bio Recent Development Table 136. List Labs Company Information Table 137. List Labs Business Overview Table 138. List Labs Living Biological Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. List Labs Living Biological Drugs Product Portfolio Table 140. List Labs Recent Development Table 141. MatriSys Bioscience Company Information Table 142. MatriSys Bioscience Business Overview Table 143. MatriSys Bioscience Living Biological Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 144. MatriSys Bioscience Living Biological Drugs Product Portfolio Table 145. MatriSys Bioscience Recent Development Table 146. North America Living Biological Drugs Revenue by Type (2021-2026) & (US$ Million) Table 147. North America Living Biological Drugs Revenue by Type (2027-2032) & (US$ Million) Table 148. North America Living Biological Drugs Revenue by Application (2021-2026) & (US$ Million) Table 149. North America Living Biological Drugs Revenue by Application (2027-2032) & (US$ Million) Table 150. North America Living Biological Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 151. North America Living Biological Drugs Revenue by Country (2021-2026) & (US$ Million) Table 152. North America Living Biological Drugs Revenue by Country (US$ Million) & (2027-2032) Table 153. Europe Living Biological Drugs Revenue by Type (2021-2026) & (US$ Million) Table 154. Europe Living Biological Drugs Revenue by Type (2027-2032) & (US$ Million) Table 155. Europe Living Biological Drugs Revenue by Application (2021-2026) & (US$ Million) Table 156. Europe Living Biological Drugs Revenue by Application (2027-2032) & (US$ Million) Table 157. Europe Living Biological Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 158. Europe Living Biological Drugs Revenue by Country (2021-2026) & (US$ Million) Table 159. Europe Living Biological Drugs Revenue by Country (US$ Million) & (2027-2032) Table 160. China Living Biological Drugs Revenue by Type (2021-2026) & (US$ Million) Table 161. China Living Biological Drugs Revenue by Type (2027-2032) & (US$ Million) Table 162. China Living Biological Drugs Revenue by Application (2021-2026) & (US$ Million) Table 163. China Living Biological Drugs Revenue by Application (2027-2032) & (US$ Million) Table 164. Asia Living Biological Drugs Revenue by Type (2021-2026) & (US$ Million) Table 165. Asia Living Biological Drugs Revenue by Type (2027-2032) & (US$ Million) Table 166. Asia Living Biological Drugs Revenue by Application (2021-2026) & (US$ Million) Table 167. Asia Living Biological Drugs Revenue by Application (2027-2032) & (US$ Million) Table 168. Asia Living Biological Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 169. Asia Living Biological Drugs Revenue by Region (US$ Million) & (2021-2026) Table 170. Asia Living Biological Drugs Revenue by Region (US$ Million) & (2027-2032) Table 171. SAMEA Living Biological Drugs Revenue by Type (2021-2026) & (US$ Million) Table 172. SAMEA Living Biological Drugs Revenue by Type (2027-2032) & (US$ Million) Table 173. SAMEA Living Biological Drugs Revenue by Application (2021-2026) & (US$ Million) Table 174. SAMEA Living Biological Drugs Revenue by Application (2027-2032) & (US$ Million) Table 175. SAMEA Living Biological Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 176. SAMEA Living Biological Drugs Revenue by Country (2021-2026) & (US$ Million) Table 177. SAMEA Living Biological Drugs Revenue by Country (US$ Million) & (2027-2032) Table 178. Research Programs/Design for This Report Table 179. Authors List of This Report Table 180. Secondary Sources Table 181. Primary Sources List of Figures Figure 1. Living Biological Drugs Image Figure 2. Global Living Biological Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Living Biological Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Single Strain Image Figure 5. Multi Strain Image Figure 6. Co-Culture Image Figure 7. Global Living Biological Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Living Biological Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Digestive System Image Figure 10. Urinary System Image Figure 11. Skin System Image Figure 12. Global Living Biological Drugs Market Size (US$ Million) & (2021-2032) Figure 13. Global Living Biological Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Living Biological Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Living Biological Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Living Biological Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Living Biological Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Living Biological Drugs Revenue Market Share by Type (2021-2032) Figure 20. Global Living Biological Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Living Biological Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Living Biological Drugs Revenue Market Share by Application (2021-2032) Figure 23. North America Living Biological Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Living Biological Drugs Revenue Share by Type (2021-2032) Figure 25. North America Living Biological Drugs Revenue Share by Application (2021-2032) Figure 26. North America Living Biological Drugs Revenue Share by Country (2021-2032) Figure 27. United States Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Living Biological Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Living Biological Drugs Revenue Share by Type (2021-2032) Figure 32. Europe Living Biological Drugs Revenue Share by Application (2021-2032) Figure 33. Europe Living Biological Drugs Revenue Share by Country (2021-2032) Figure 34. Germany Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Living Biological Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Living Biological Drugs Revenue Share by Type (2021-2032) Figure 44. China Living Biological Drugs Revenue Share by Application (2021-2032) Figure 45. Asia Living Biological Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Living Biological Drugs Revenue Share by Type (2021-2032) Figure 47. Asia Living Biological Drugs Revenue Share by Application (2021-2032) Figure 48. Asia Living Biological Drugs Revenue Share by Region (2021-2032) Figure 49. Japan Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Living Biological Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Living Biological Drugs Revenue Share by Type (2021-2032) Figure 57. SAMEA Living Biological Drugs Revenue Share by Application (2021-2032) Figure 58. SAMEA Living Biological Drugs Revenue Share by Country (2021-2032) Figure 59. Brazil Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Living Biological Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Single Strain
  • Multi Strain
  • Co-Culture
Applications
  • Digestive System
  • Urinary System
  • Skin System
Companies covered
  • Ardeypharman
  • Miyarisan Pharmaceutical
  • Ferring Pharmaceuticals
  • Seres Therapeutics
  • Infant Bacterial Therapeutics
  • Osel
  • Takeda
  • AOBiome
  • Synlogic
  • Finch Therapeutics
  • Capsugel
  • Jeneil Biotech
  • UAS Labs
  • Biose
  • Cerbios-Pharma
  • Inpac Probiotics
  • NIZO
  • Winclove Probiotics
  • BJP Laboratories
  • Luina Bio
  • List Labs
  • MatriSys Bioscience

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Living Biological Drugs Market by Type
  3. 1.2.1 Global Living Biological Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Single Strain
  5. 1.2.3 Multi Strain
  6. 1.2.4 Co-Culture
  7. 1.3 Living Biological Drugs Market by Application
  8. 1.3.1 Global Living Biological Drugs Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Digestive System
  10. 1.3.3 Urinary System
  11. 1.3.4 Skin System
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Living Biological Drugs Market Dynamics
  1. 2.1 Living Biological Drugs Industry Trends
  2. 2.2 Living Biological Drugs Industry Drivers
  3. 2.3 Living Biological Drugs Industry Opportunities and Challenges
  4. 2.4 Living Biological Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Living Biological Drugs Market Perspective (2021-2032)
  2. 3.2 Global Living Biological Drugs Growth Trends by Region
  3. 3.2.1 Global Living Biological Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Living Biological Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Living Biological Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Living Biological Drugs Revenue by Players
  2. 4.1.1 Global Living Biological Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Living Biological Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Living Biological Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Living Biological Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Living Biological Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Living Biological Drugs Players, Product Type & Application
  8. 4.5 Global Living Biological Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Living Biological Drugs Market CR5 and HHI
  11. 4.6.3 2025 Living Biological Drugs Tier 1, Tier 2, and Tier 3
5 Living Biological Drugs Market Size by Type
  1. 5.1 Global Living Biological Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Living Biological Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Living Biological Drugs Revenue Market Share by Type (2021-2032)
6 Living Biological Drugs Market Size by Application
  1. 6.1 Global Living Biological Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Living Biological Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Living Biological Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Ardeypharman
  2. 7.1.1 Ardeypharman Company Information
  3. 7.1.2 Ardeypharman Business Overview
  4. 7.1.3 Ardeypharman Living Biological Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Ardeypharman Living Biological Drugs Product Portfolio
  6. 7.1.5 Ardeypharman Recent Developments
  7. 7.2 Miyarisan Pharmaceutical
  8. 7.2.1 Miyarisan Pharmaceutical Company Information
  9. 7.2.2 Miyarisan Pharmaceutical Business Overview
  10. 7.2.3 Miyarisan Pharmaceutical Living Biological Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Miyarisan Pharmaceutical Living Biological Drugs Product Portfolio
  12. 7.2.5 Miyarisan Pharmaceutical Recent Developments
  13. 7.3 Ferring Pharmaceuticals
  14. 7.3.1 Ferring Pharmaceuticals Company Information
  15. 7.3.2 Ferring Pharmaceuticals Business Overview
  16. 7.3.3 Ferring Pharmaceuticals Living Biological Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Ferring Pharmaceuticals Living Biological Drugs Product Portfolio
  18. 7.3.5 Ferring Pharmaceuticals Recent Developments
  19. 7.4 Seres Therapeutics
  20. 7.4.1 Seres Therapeutics Company Information
  21. 7.4.2 Seres Therapeutics Business Overview
  22. 7.4.3 Seres Therapeutics Living Biological Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Seres Therapeutics Living Biological Drugs Product Portfolio
  24. 7.4.5 Seres Therapeutics Recent Developments
  25. 7.5 Infant Bacterial Therapeutics
  26. 7.5.1 Infant Bacterial Therapeutics Company Information
  27. 7.5.2 Infant Bacterial Therapeutics Business Overview
  28. 7.5.3 Infant Bacterial Therapeutics Living Biological Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Infant Bacterial Therapeutics Living Biological Drugs Product Portfolio
  30. 7.5.5 Infant Bacterial Therapeutics Recent Developments
  31. 7.6 Osel
  32. 7.6.1 Osel Company Information
  33. 7.6.2 Osel Business Overview
  34. 7.6.3 Osel Living Biological Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Osel Living Biological Drugs Product Portfolio
  36. 7.6.5 Osel Recent Developments
  37. 7.7 Takeda
  38. 7.7.1 Takeda Company Information
  39. 7.7.2 Takeda Business Overview
  40. 7.7.3 Takeda Living Biological Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Takeda Living Biological Drugs Product Portfolio
  42. 7.7.5 Takeda Recent Developments
  43. 7.8 AOBiome
  44. 7.8.1 AOBiome Company Information
  45. 7.8.2 AOBiome Business Overview
  46. 7.8.3 AOBiome Living Biological Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 AOBiome Living Biological Drugs Product Portfolio
  48. 7.8.5 AOBiome Recent Developments
  49. 7.9 Synlogic
  50. 7.9.1 Synlogic Company Information
  51. 7.9.2 Synlogic Business Overview
  52. 7.9.3 Synlogic Living Biological Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Synlogic Living Biological Drugs Product Portfolio
  54. 7.9.5 Synlogic Recent Developments
  55. 7.10 Finch Therapeutics
  56. 7.10.1 Finch Therapeutics Company Information
  57. 7.10.2 Finch Therapeutics Business Overview
  58. 7.10.3 Finch Therapeutics Living Biological Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Finch Therapeutics Living Biological Drugs Product Portfolio
  60. 7.10.5 Finch Therapeutics Recent Developments
  61. 7.11 Capsugel
  62. 7.11.1 Capsugel Company Information
  63. 7.11.2 Capsugel Business Overview
  64. 7.11.3 Capsugel Living Biological Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Capsugel Living Biological Drugs Product Portfolio
  66. 7.11.5 Capsugel Recent Developments
  67. 7.12 Jeneil Biotech
  68. 7.12.1 Jeneil Biotech Company Information
  69. 7.12.2 Jeneil Biotech Business Overview
  70. 7.12.3 Jeneil Biotech Living Biological Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Jeneil Biotech Living Biological Drugs Product Portfolio
  72. 7.12.5 Jeneil Biotech Recent Developments
  73. 7.13 UAS Labs
  74. 7.13.1 UAS Labs Company Information
  75. 7.13.2 UAS Labs Business Overview
  76. 7.13.3 UAS Labs Living Biological Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 UAS Labs Living Biological Drugs Product Portfolio
  78. 7.13.5 UAS Labs Recent Developments
  79. 7.14 Biose
  80. 7.14.1 Biose Company Information
  81. 7.14.2 Biose Business Overview
  82. 7.14.3 Biose Living Biological Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Biose Living Biological Drugs Product Portfolio
  84. 7.14.5 Biose Recent Developments
  85. 7.15 Cerbios-Pharma
  86. 7.15.1 Cerbios-Pharma Company Information
  87. 7.15.2 Cerbios-Pharma Business Overview
  88. 7.15.3 Cerbios-Pharma Living Biological Drugs Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Cerbios-Pharma Living Biological Drugs Product Portfolio
  90. 7.15.5 Cerbios-Pharma Recent Developments
  91. 7.16 Inpac Probiotics
  92. 7.16.1 Inpac Probiotics Company Information
  93. 7.16.2 Inpac Probiotics Business Overview
  94. 7.16.3 Inpac Probiotics Living Biological Drugs Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Inpac Probiotics Living Biological Drugs Product Portfolio
  96. 7.16.5 Inpac Probiotics Recent Developments
  97. 7.17 NIZO
  98. 7.17.1 NIZO Company Information
  99. 7.17.2 NIZO Business Overview
  100. 7.17.3 NIZO Living Biological Drugs Revenue and Gross Margin (2021-2026)
  101. 7.17.4 NIZO Living Biological Drugs Product Portfolio
  102. 7.17.5 NIZO Recent Developments
  103. 7.18 Winclove Probiotics
  104. 7.18.1 Winclove Probiotics Company Information
  105. 7.18.2 Winclove Probiotics Business Overview
  106. 7.18.3 Winclove Probiotics Living Biological Drugs Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Winclove Probiotics Living Biological Drugs Product Portfolio
  108. 7.18.5 Winclove Probiotics Recent Developments
  109. 7.19 BJP Laboratories
  110. 7.19.1 BJP Laboratories Company Information
  111. 7.19.2 BJP Laboratories Business Overview
  112. 7.19.3 BJP Laboratories Living Biological Drugs Revenue and Gross Margin (2021-2026)
  113. 7.19.4 BJP Laboratories Living Biological Drugs Product Portfolio
  114. 7.19.5 BJP Laboratories Recent Developments
  115. 7.20 Luina Bio
  116. 7.20.1 Luina Bio Company Information
  117. 7.20.2 Luina Bio Business Overview
  118. 7.20.3 Luina Bio Living Biological Drugs Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Luina Bio Living Biological Drugs Product Portfolio
  120. 7.20.5 Luina Bio Recent Developments
  121. 7.21 List Labs
  122. 7.21.1 List Labs Company Information
  123. 7.21.2 List Labs Business Overview
  124. 7.21.3 List Labs Living Biological Drugs Revenue and Gross Margin (2021-2026)
  125. 7.21.4 List Labs Living Biological Drugs Product Portfolio
  126. 7.21.5 List Labs Recent Developments
  127. 7.22 MatriSys Bioscience
  128. 7.22.1 MatriSys Bioscience Company Information
  129. 7.22.2 MatriSys Bioscience Business Overview
  130. 7.22.3 MatriSys Bioscience Living Biological Drugs Revenue and Gross Margin (2021-2026)
  131. 7.22.4 MatriSys Bioscience Living Biological Drugs Product Portfolio
  132. 7.22.5 MatriSys Bioscience Recent Developments
8 North America
  1. 8.1 North America Living Biological Drugs Revenue (2021-2032)
  2. 8.2 North America Living Biological Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Living Biological Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Living Biological Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Living Biological Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Living Biological Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Living Biological Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Living Biological Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Living Biological Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Living Biological Drugs Revenue by Country
  11. 8.6.1 North America Living Biological Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Living Biological Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Living Biological Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Living Biological Drugs Revenue (2021-2032)
  2. 9.2 Europe Living Biological Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Living Biological Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Living Biological Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Living Biological Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Living Biological Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Living Biological Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Living Biological Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Living Biological Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Living Biological Drugs Revenue by Country
  11. 9.6.1 Europe Living Biological Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Living Biological Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Living Biological Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Living Biological Drugs Revenue (2021-2032)
  2. 10.2 China Living Biological Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Living Biological Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Living Biological Drugs Revenue by Type (2027-2032)
  5. 10.3 China Living Biological Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Living Biological Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Living Biological Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Living Biological Drugs Revenue by Application (2027-2032)
  9. 10.5 China Living Biological Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Living Biological Drugs Revenue (2021-2032)
  2. 11.2 Asia Living Biological Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Living Biological Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Living Biological Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Living Biological Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Living Biological Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Living Biological Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Living Biological Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Living Biological Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Living Biological Drugs Revenue by Country
  11. 11.6.1 Asia Living Biological Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Living Biological Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Living Biological Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Living Biological Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Living Biological Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Living Biological Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Living Biological Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Living Biological Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Living Biological Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Living Biological Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Living Biological Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Living Biological Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Living Biological Drugs Revenue by Country
  11. 12.6.1 SAMEA Living Biological Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Living Biological Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Living Biological Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst